

14 February 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Submission of un-audited financial results (both standalone and consolidated) for the quarter ended 31 December 2021, along with Limited Review Report as on that date

Dear Sir/Madam,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable circular(s), we herewith enclose the following:

- Un-audited financial results (both standalone and consolidated) for the quarter year ended 31 December 2021;
- Limited Review Reports thereon, as on 31 December 2021.

The aforesaid financial results and statements are duly approved and recommended by the Audit Committee in their meeting held on 14 February 2022.

These are also being made available on the website of the Company at www.bankabio.com

Kindly take the same on record.

Thank you!

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary and Compliance Officer

Encls. as above



Independent Auditor's Review Report on Quarterly Unaudited Standalone and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of **Banka BioLoo Limited**,


We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **BANKA BIOLOO LIMITED** for the quarter and nine months ended December, 2021 ("the statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India, other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular"), including the manner in which it is to be disclosed, or that it contains any material misstatements.

For **PRSV & Co LLP**
Chartered Accountants
Firm Registration No. S200016


Y. Venkateswarlu
Partner
M. No. 222068



Place: Hyderabad
Date: 14 February 2022
UDIN: 2222068ACBJKI7626

BANKA BIOLOO LIMITED

Unaudited STANDALONE Statement of Financial Results for the quarter ended 31 December 2021

(Rs. In Lakhs)

S. No	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2021 Unaudited	30.09.2021 Unaudited	31.12.2020 Unaudited	31.12.2021 Unaudited	31.12.2020 Unaudited	31.03.2021 Audited
1	Income						
	Gross Revenue from operations	1152.43	1192.98	840.39	3260.87	2440.47	3,566.53
	Less:Duties & Taxes	(147.01)	(161.69)	(81.24)	(421.16)	(357.33)	(520.77)
	Revenue from Operations	1005.42	1031.29	759.16	2839.71	2083.14	3,045.76
	Other operating revenue						-
	Other income	13.88	9.26	14.34	35.19	27.27	57.61
	Total Income	1019.31	1040.55	773.50	2874.90	2110.41	3,103.37
2	Expenses						
	Cost of materials consumed	223.03	298.08	204.71	668.64	421.05	702.22
	Changes in inventories of finished goods & work-in-progress	(25.60)	(61.48)	(81.45)	(94.16)	(128.37)	(321.13)
	Employee benefits expense	478.53	445.98	290.70	1273.73	910.11	1,302.45
	Finance costs	48.86	46.75	34.15	136.75	102.61	151.45
	Depreciation and amortisation expense	25.86	20.68	13.59	66.34	39.46	59.73
	Other expenses	192.04	206.92	275.38	606.81	590.09	1,021.65
	Total expenses	942.73	956.92	737.08	2658.11	1934.95	2,916.37
3	Profit/(loss) before tax	76.58	83.63	36.43	216.79	175.46	187.00
4	Tax expense						
	(1) Current tax	19.15			19.15	33.70	-
	(2) Taxes for earlier years						(19.29)
	(3) MAT Credit						-
	(4) Deferred tax	4.67	(5.66)	(0.79)	(9.61)	(7.95)	(14.36)
	Total Tax expense	23.81	-5.66	-0.79	9.54	25.75	(33.64)
5	Profit after tax	52.77	89.29	37.22	207.25	149.71	220.64
	Other comprehensive income						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations						27.16
	Income tax effect on items that will not be reclassified to						(6.65)
	Other comprehensive income for the year	-	-	-	-	-	20.51
	Total comprehensive income for the year	52.77	89.29	37.22	207.25	149.71	241.15
6	Paid up equity share capital (Face value Rs. 10/- each)	1028.11	1028.11	1028.11	1028.11	1028.11	1,028.11
7	Earnings per share						
	Basic and Diluted Earnings per share (in Rs.)	0.51	0.87	0.36	2.02	1.46	2.15
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)


 For PRSV & Co. LLP
 Chartered Accountants
 FRN No. S-200016

 Y. Venkateswarlu
 Partner
 M.No.222068

 Place: Hyderabad
 Date: 14.02.2022


FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka

 Vishal Murarka
 CEO & Executive Director
 DIN: 06729485


Notes:

1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 14 February 2022.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter and nine months ended 31 December 2021 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31st March 2021.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to manufacturing, supplying and installation of Bio toilets and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. During the financial year ended 31st March 2018, the company has completed its initial public Offer (IPO) of 10,98,000 Equity Shares of Rs.10/- each at a price of Rs.115 per share (including a premium of Rs.105 per share).
7. Proceeds from Initial Public Offer of Equity Shares have been utilized as under:


S. No	Particulars	Projected Utilization of Funds as per Prospectus	Actual Utilization of Funds till 31.12.2021	Deviation/ Variation (if any)
1	Long Term Working Capital Requirement	797.88	797.88	
2	General Corporate Purpose	231.62	231.62	
3	Issue Related Expenses-Company portion	61.10	61.08	
4	Capital expenditure at existing inoculum at Aler	75.21	75.21	
5	Capital expenditure at proposed new unit at Ibrahimpatnam	96.89	26.42	
	Total	1,262.70	1192.21	-

8. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets,
9. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka BioLoo Limited



Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 14 February 2022



Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of **Banka BioLoo Limited**,

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **BANKA BIOLOO LIMITED** (The "Holding Company") and its subsidiary (The Holding Company and its subsidiaries and its associate together referred to as the "Group") for the quarter and nine months ended 31 December 2021 a ("the statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India, other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

The Statement includes the results of the following entities.

Subsidiary

Banka Earth Foundation

Associate

Sai Banka SPV Private Limited
Sustainable Sanitation Industry Association

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular'), including the manner in which it is to be disclosed, or that it contains any material misstatements.

The accompanying statement includes the unaudited interim financial results and other financial information of 1 wholly owned subsidiary whose unaudited interim financial results include total

T. Vard

revenues of Rs. 80,873 and total net profit after tax of Rs. 5,358 and other comprehensive income of Rs. Nil and total comprehensive income of Rs. 5,358 for the quarter ended 31 December, 2021 as considered in the consolidated unaudited financial results. These interim financial results and other financial information are unaudited and have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this wholly owned subsidiary, is based solely on that unaudited financial statement/financial information furnished by the Management.

For PRSV & Co LLP
Chartered Accountants
Firm Registration No. S200016




Y. Venkateswarlu
Partner
M. No. 222068

Place: Hyderabad
Date: 14 February 2022

UDIN: 2222068ACBTNN5182

BANKA BIOLOO LIMITED

Unaudited CONSOLIDATED Statement of Financial Results for the quarter ended 31 December 2021

(Rs. In Lakhs)

S. No	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2021 Unaudited	30.09.2021 Unaudited	31.12.2020 Unaudited	31.12.2021 Unaudited	31.12.2020 Unaudited	31.03.2021 Audited
1	Income						
	Gross Revenue from operations	1,152.43	1,192.98	840.39	3,260.87	2,440.5	3,566.53
	Less:Duties & Taxes	(147.01)	(161.69)	(81.24)	(421.16)	(357.33)	-520.77
	Revenue from Operations	1,005.42	1,031.29	759.16	2,839.71	2,083.1	3,045.76
	Other operating revenue		-	-		-	-
	Other income	14.69	9.26	14.35	36.00	27.3	57.62
	Total Income	1,020.11	1,040.55	773.50	2,875.71	2,110.41	3,103.38
2	Expenses						
	Cost of materials consumed	223.03	298.08	204.71	668.64	421.0	702.22
	Changes in inventories of finished goods & work-in-progress	(25.60)	(61.48)	(81.45)	(94.16)	(128.37)	-321.13
	Employee benefits expense	478.53	445.98	290.70	1,273.73	910.1	1,302.45
	Finance costs	48.86	46.75	34.15	136.75	102.6	151.45
	Depreciation and amortisation expense	25.86	20.68	13.59	66.34	39.5	59.73
	Other expenses	192.79	206.92	275.38	607.57	590.1	1,021.65
	Total expenses	943.48	956.92	737.08	2,658.86	1,934.95	2,916.37
3	Share of profit/(loss) of Associates	(0.20)	(0.93)	-	(1.75)	-	(0.17)
4	Profit/(loss) before tax	76.43	82.69	36.43	215.10	175.46	186.84
5	Tax expense						
	(1) Current tax	19.15	-	-	19.15	33.7	-
	(2) Taxes for earlier years		-	-		-	-19.29
	(3) MAT Credit		-	-		-	-
	(4) Deferred tax	4.67	-5.66	-0.79	-9.61	-8.0	-14.36
	Total Tax expense	23.81	-5.66	-0.79	9.54	25.75	(33.64)
6	Profit after tax	52.62	88.35	37.22	205.56	149.71	220.48
	Other comprehensive income						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations						27.16
	Income tax effect on items that will not be reclassified						-6.65
	Other comprehensive income for the year						20.51
	Total comprehensive income for the year	52.62	88.35	37.22	205.56	149.71	240.99
	Attributable to						
	Shareholders of the Company	52.62	88.35	37.22	205.56	149.71	240.99
	Non controlling interest	-	-	-	0.00	0.00	0.00
7	Paid up equity share capital (Face value Rs. 10/- each)	1,028.1	1,028.1	1,028.1	1,028.1	1,028.1	1,028.11
8	Earnings per share						
	Basic and Diluted Earnings per share (in Rs.)	0.51	0.86	0.36	2.00	1.46	2.14
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

FOR & ON BEHALF OF BOARD OF DIRECTORS

For PRSV & Co. LLP
Chartered Accountants
FRN No. S-200016

Y. Venkateswarlu
Partner
M.No.222068



Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 14.02.2022

Notes:

1. The above statement of Audited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 14 December 2021.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The consolidated financial results of the Group include the results of the Company and results of the following entities.


Name of the entity	Status
Banka Earth Foundation	Subsidiary
Sai Banka SPV Pvt Ltd	Associate
Sustainable Sanitation Industry Association	Associate

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
5. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets,
6. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For **Banka BioLoo Limited**



Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 14 February 2022

14 February 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051


Symbol: Banka**Sub: Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 31 December 2021**

Dear Sir/Madam,

With reference to the above-cited subject, please find enclosed herewith the statement of deviation(s) or variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 31 December 2021.

This is for your information and necessary records.

Thank you!

For Banka BioLoo Limited**Sri Bala Aditya Yanamandra
Company Secretary and Compliance Officer**

STATEMENT OF DEVIATION(S) OR VARIATION(S) UNDER REGULATION 32(1) OF SEBI (LODR) REGULATIONS, 2015

In reference to the compliance under Regulation 32(1)(a) & (b) of SEBI (LODR) Regulations, 2015, as required under regulation 32(8) of SEBI (LODR) Regulations, 2015, the Company hereby submits to National Stock Exchange, statement of deviation(s) or variation(s) for the quarter ended 31 December 2021.

- a) **Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;**

We, hereby, inform you that there was no deviation in the utilisation of the proceeds of the public issue from the objects stated in the prospectus of the issue, as required under regulation 32(1)(a) of SEBI (LODR) Regulations, 2015.

- b) **Indicating category-wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilisation of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable, and the actual utilisation of funds**

We, hereby, inform that there has been no variation in the use of the proceeds from the objects stated in the prospectus dated 23 January 2018, or explanatory statement to the notice of the Extra-Ordinary Meeting dated 16 November 2017, issued for Initial Public offering of Securities, as per regulation 32(1)(b) of SEBI (LODR) Regulations, 2015.

Thank you!

For Banka BioLoo Limited



Vishal Murarka
CEO & Executive Director
DIN:06729485